title: IMP3 expression in gastric cancer: association with clinicopathological features and HER2 status.
abstract: BACKGROUND
  The aim of this study was to evaluate the expression of IMP3, an independent poor prognostic factor for many cancers, and its association with clinicopathological features and HER2 status.
  
  
  METHODS
  Gastrectomy specimens from 106 patients were evaluated by immunohistochemistry and fluorescence in situ hybridization.
  
  
  RESULTS
  HER2 overexpression was found in 4.71 % of the samples. A negative association was observed between HER2 overexpression and grade of differentiation. No association was observed between HER2 overexpression and status of surgical margins, vascular invasion, perineural invasion, nodal metastasis and depth of invasion. Among all specimens of gastric cancer, 67.92 % were positive for IMP3. Expression of IMP3 was significantly higher in specimens with vascular invasion, perineural invasion, nodal metastasis and higher depth of invasion. HER2 overexpression was detected in only 5.55 % of IMP3 positive specimens.
  
  
  CONCLUSIONS
  IMP3 expression was frequently observed in gastric cancer and was associated with poor prognostic clinicopathological features. A survival benefit with HER2 therapy should be expected for the minority of patients with IMP3 positive specimens. Studies should be conducted to evaluate the response to HER2 therapy of gastric cancer expressing IMP3.
authors.affiliation: Pathological Anatomy Center, University Hospital of Brasilia (UNB), Via L2 Norte, SGAN 604/605, Brasília, DF, CEP 70840-050, Brazil.
authors.forename: Emanuel Adelino M
authors.initials: EA
authors.lastname: Damasceno
authors.forename: Fabiana Pirani
authors.initials: FP
authors.lastname: Carneiro
authors.forename: Albino Verçosa de
authors.initials: AV
authors.lastname: Magalhães
authors.forename: Marcos de Vasconcelos
authors.initials: Mde V
authors.lastname: Carneiro
authors.forename: Gustavo Henrique Soares
authors.initials: GH
authors.lastname: Takano
authors.forename: Leonora Maciel de Sousa
authors.initials: LM
authors.lastname: Vianna
authors.forename: Heinrich Bender Kohnert
authors.initials: HB
authors.lastname: Seidler
authors.forename: Tercia Maria Mendes Lousa de
authors.initials: TM
authors.lastname: Castro
authors.forename: Maria Imaculada
authors.initials: MI
authors.lastname: Muniz-Junqueira
authors.forename: Rivadávio Fernandes Batista
authors.initials: RF
authors.lastname: Amorim
authors.forename: Vânia Maria Moraes
authors.initials: VM
authors.lastname: Ferreira
authors.forename: Andrea Barreto
authors.initials: AB
authors.lastname: Motoyama
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D011379:Prognosis; D016601:RNA-Binding Proteins / Q000032:analysis*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D013274:Stomach Neoplasms / Q000737:chemistry / Q000401:mortality / Q000473:pathology*
chemical_list: D016601:RNA-Binding Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; C498780:IGF2BP3 protein, human; C508053:ERBB2 protein, human